# AOD-9604

AOD-9604 is a peptide made in a lab: a short chain of 16 amino acids built from the tail end of human growth hormone. Researchers at Monash University first reported rat and mouse studies of it between 2000 and 2001. This hub answers common questions in plain words. It draws on published studies, a human trial safety report, a company announcement about its human obesity trial, and Australian, US and sport records.

| | |
| --- | --- |
| Common name | AOD-9604 |
| Name origin | Anti-obesity drug 9604 (Mendias and Awan, Sports Medicine, 2026) |
| Structure | Amino acids 177 to 191 of human growth hormone plus one tyrosine at the N-terminal end (Cox et al., 2015) |
| CAS number | 221231-10-3 (Poisons Standard, October 2026) |
| Earliest studies found in PubMed | Ng et al., Hormone Research, 2000; Heffernan et al., 2001 |
| Human obesity trial | Phase 2b, 24 weeks, tablets; sponsor announcement of 21 February 2007 reported the primary endpoint was not met |
| ClinicalTrials.gov name search | No records for AOD-9604 or AOD9604 (16 October 2026); OPTIONS is registered on ANZCTR as ACTRN12605000067673 |
| Human safety publication | Stier et al., Journal of Endocrinology and Metabolism, 2013; sponsor-funded trials |
| Published human half-life | Not established in the sources read |
| Poisons Standard, October 2026 | Named in Schedule 4 and in Appendix D, clause 5 (F2026L01327) |
| WADA 2026 Prohibited List | Named at S2.2.3; prohibited at all times |

## Articles in this hub

- [AOD-9604 side effects: what trials, the FDA and regulators have recorded](https://www.formlaboratories.com/learn/aod-9604/aod-9604-side-effects) - AOD-9604 side effects and safety: what the sponsor reported from its human obesity trial, what the FDA wrote, what rat and mouse studies measured, and what no source establishes.
- [AOD-9604 study findings: what the human obesity trial reported and what animal studies measured](https://www.formlaboratories.com/learn/aod-9604/aod-9604-study-findings) - What studies of AOD-9604 reported: the rat and mouse papers, the 24-week human obesity trial that a company announcement said missed its primary endpoint, the registry records, and the gaps.
- [How does AOD-9604 work? What rat and mouse studies measured](https://www.formlaboratories.com/learn/aod-9604/how-aod-9604-works) - How AOD-9604 is said to work: what the rat and mouse papers measured about fat breakdown, the growth hormone receptor and the beta-3 adrenergic receptor, and what is not established in people.
- [Is AOD-9604 legal in Australia? Poisons Standard, TGA, FDA and WADA records](https://www.formlaboratories.com/learn/aod-9604/is-aod-9604-legal-in-australia) - What the October 2026 Poisons Standard, the TGA, the FDA and the WADA 2026 Prohibited List record about AOD-9604, with the date each record was checked. Records only; this is not legal advice.
- [What is AOD-9604? The growth hormone fragment peptide explained from the research](https://www.formlaboratories.com/learn/aod-9604/what-is-aod-9604) - What AOD-9604 is: a 16-amino-acid peptide built from the tail end of human growth hormone, who developed it, how it differs from growth hormone, and where the evidence stops.

---

Canonical page: https://www.formlaboratories.com/learn/aod-9604

Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide.

- Site guide for agents: https://www.formlaboratories.com/llms.txt
- Sitemap: https://www.formlaboratories.com/sitemap.xml
- Full catalogue: https://www.formlaboratories.com/shop
- Contact: hello@formlaboratories.com

All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.